Below was my response to a post from a long that s
Post# of 72440
" I would suggest the success of the pill will help pharmas price ONLY the value of Brilacidin for IBD, not the entire Brilacidin franchise as there are as yet many areas of Brilacidin not developed that could increase its value many times over to include dermatology, eye and ear infections,COPD,and a host of other revenue streams not yet considered.
We have to keep in mind Brilacidin is not a one trick pony, it in itself is a whole herd of possibilities.
That is why many longs feel Brilacidin, even if it achieves a very lucrative licensing deal for the IBD franchise, will still be showing only the tip of the iceberg as to its overall value and why many have said it could be a drug for the ages.
Kind of like what Jackie Gleason use to say at the start of his show "...and away we go".
Fun position to be in for all longs."